PT-141 (Bremelanotide) vs BNP (B-type Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | BNP (B-type Natriuretic Peptide) |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. |
| Best For |
What They Have in Common
Both PT-141 (Bremelanotide) and BNP (B-type Natriuretic Peptide) are commonly used for: